About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Study Evaluating Etanercept in Moderate to Severe Asthma

Study Evaluating Etanercept in Moderate to Severe Asthma

NCT00141791·13 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Moderate to severe persistent asthma for at least 1 year
Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted
Subjects must be on a high-dose inhaled corticosteroid (ICS)

You may not be if

Previous treatment with etanercept
Current use of cigarettes
Significant concurrent medical conditions at the time of screening

The record

StatusCompleted

PhasePhase 2

Taking part120

StartedMay 2005

UpdatedAug 7, 2009

Conditions

Where13

Birmingham, Alabama, United States
Denver, Colorado, United States
Sarasota, Florida, United States